Blurbs

Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), Cardinal Health (CAH) and Beam Therapeutics (BEAM)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Illumina (ILMNResearch Report), Cardinal Health (CAHResearch Report) and Beam Therapeutics (BEAMResearch Report).

Illumina (ILMN)

Morgan Stanley analyst Tejas Savant maintained a Hold rating on Illumina today and set a price target of $225.00. The company’s shares closed last Monday at $215.91.

According to TipRanks.com, Savant is ranked 0 out of 5 stars with an average return of -13.3% and a 30.7% success rate. Savant covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Ginkgo Bioworks Holdings, and Adaptive Biotechnologies.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Illumina with a $254.00 average price target, representing a 13.6% upside. In a report issued on November 4, Robert W. Baird also maintained a Hold rating on the stock with a $210.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Cardinal Health (CAH)

In a report released today, Erin Wright from Morgan Stanley maintained a Buy rating on Cardinal Health, with a price target of $82.00. The company’s shares closed last Monday at $81.21.

According to TipRanks.com, Wright is a 5-star analyst with an average return of 15.8% and a 64.3% success rate. Wright covers the Healthcare sector, focusing on stocks such as Phibro Animal Health, Quest Diagnostics, and SmileDirectClub.

The word on The Street in general, suggests a Hold analyst consensus rating for Cardinal Health with a $75.50 average price target.

Beam Therapeutics (BEAM)

SVB Securities analyst Mani Foroohar maintained a Buy rating on Beam Therapeutics today and set a price target of $81.00. The company’s shares closed last Monday at $38.91, close to its 52-week low of $27.77.

According to TipRanks.com, Foroohar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -15.4% and a 39.4% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, 4D Molecular Therapeutics, and Rocket Pharmaceuticals.

Beam Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $77.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ILMN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More